August 2025 - 12 articles
Left: Demonstration of the molecular context of radioligands targeting (A) fibroblast activation protein (FAP); (B) hypoxia; (C) gastrin-releasing peptide receptor (GRPr); and (D) integrin. Each process is part of the complex tumor microenvironment, which allows for high tumor-to-background uptake ratios on PET imaging.
Right: Representative images obtained from a patient with non-small-cell lung cancer demonstrating radiotracer-avid primary lung neoplasm at the left lung apex (arrows). (A–B) Fluorine 18 (18F)-labeled Fluoromisonidazole (FMISO) PET/CT images. (A) 18F–FMISO axial PET image; (B) axial fused 18F-FMISO PET/CT image with an SUV max of 2.5. (C–D) Fluorine 18 (18F)-labeled Fluorodeoxyglucose (FDG) PET/CT images of the same patient performed 1 week prior. (C) 18F-FDG axial PET image; (D) axial fused 18F-FDG PET/CT image demonstrating intense avidity with an SUV max of 24. View this paper
Targeted radioligand therapy (RLT) is an emerging field in anticancer therapeutics with great potential across tumor types and stages of disease. While much progress has focused on agents targeting somatostatin receptors and prostate-specific membran...
Background/Objectives: Myelofibrosis (MF) is a myeloproliferative neoplasm characterized by the replacement of healthy bone marrow (BM) with malignant and fibrotic tissue. In a healthy state, bone marrow is composed of approximately 60–70% fat...
of 2
Get Alerted
Add your email address to receive forthcoming issues of this journal.
